Iovance Biotherapeutics (IOVA) closed at $14.86 on October 20, 2026, up 4.6% from the previous close, on volume of 9,457,041 shares (30-day average 15,823,876).
Data as of October 20, 2026.
Market Chameleon (Mon, 19-Oct 3:35 AM ET)
Globe Newswire (Mon, 19-Oct 7:00 AM ET)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Fri, 16-Oct 5:15 PM ET)
Iovance Halts Pediatric TIL Trial, Nudging Investor Focus Back to Core Programs
TipRanks (Fri, 16-Oct 12:30 PM ET)
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Globe Newswire (Thu, 1-Oct 7:00 AM ET)
High-Stakes October has these Biotechs Entering Crucial Stretch
Globe Newswire (Tue, 29-Sep 12:12 PM ET)
Market Chameleon (Tue, 29-Sep 7:03 AM ET)
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Globe Newswire (Tue, 29-Sep 7:00 AM ET)
Iovance issues 179,750 inducement options at $10.02 to support new hires
Market Chameleon (Mon, 21-Sep 3:33 AM ET)
Iovance Biotherapeutics to Present at Upcoming Conferences
Globe Newswire (Fri, 4-Sep 8:00 AM ET)
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Iovance Biotherapeutics trades on the NASDAQ stock market under the symbol IOVA.
As of October 21, 2026, IOVA stock price declined to $14.74 with 4,549,797 million shares trading.
IOVA has a beta of 0.89, meaning it tends to be less sensitive to market movements. IOVA has a correlation of 0.01 to the broad based SPY ETF.
IOVA has a market cap of $6.58 billion. This is considered a Mid Cap stock.
Last quarter Iovance Biotherapeutics reported $99 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.03.
In the last 3 years, IOVA traded as high as $18.33 and as low as $1.64.
The top ETF exchange traded funds that IOVA belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.
IOVA has outperformed the market in the last year with a price return of +535.3% while the SPY ETF gained +16.0%. IOVA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +193.6% and +13.7%, respectively, while the SPY returned +4.1% and -1.1%, respectively.
IOVA support price is $14.04 and resistance is $15.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IOVA shares will trade within this expected range on the day.
